Skip to main content

Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Publication ,  Conference
Goudar, R; Keir, S; Hjelmeland, M; Conrad, C; Traxler, P; Lane, H; Wang, XF; Bigner, DD; Friedman, HS; Rich, JN
Published in: CLINICAL CANCER RESEARCH
December 1, 2003

Duke Scholars

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

December 1, 2003

Volume

9

Issue

16

Start / End Page

6090S / 6090S

Location

BOSTON, MASSACHUSETTS

Publisher

AMER ASSOC CANCER RESEARCH

Conference Name

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goudar, R., Keir, S., Hjelmeland, M., Conrad, C., Traxler, P., Lane, H., … Rich, J. N. (2003). Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. In CLINICAL CANCER RESEARCH (Vol. 9, pp. 6090S-6090S). BOSTON, MASSACHUSETTS: AMER ASSOC CANCER RESEARCH.
Goudar, R., S. Keir, M. Hjelmeland, C. Conrad, P. Traxler, H. Lane, X. F. Wang, D. D. Bigner, H. S. Friedman, and J. N. Rich. “Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” In CLINICAL CANCER RESEARCH, 9:6090S-6090S. AMER ASSOC CANCER RESEARCH, 2003.
Goudar R, Keir S, Hjelmeland M, Conrad C, Traxler P, Lane H, et al. Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. In: CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6090S-6090S.
Goudar R, Keir S, Hjelmeland M, Conrad C, Traxler P, Lane H, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6090S-6090S.

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

December 1, 2003

Volume

9

Issue

16

Start / End Page

6090S / 6090S

Location

BOSTON, MASSACHUSETTS

Publisher

AMER ASSOC CANCER RESEARCH

Conference Name

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis